GW501516 is a PPARδ agonist, not a SARM. Short human studies showed metabolic and lipid effects, but development was halted after long-term rodent carcinogenicity findings across multiple organ systems.
Key points
- Mechanism is PPARδ agonism, affecting fat oxidation and lipid handling rather than the androgen receptor.
- Short human trials reported reduced triglycerides and altered fatty acid metabolism.
- Long-duration animal studies produced tumours at multiple sites, ending clinical development.
- No human study has run long enough to address the cancer signal either way.
What the literature shows
Human studies in overweight and dyslipidaemic men reported reductions in triglycerides and improvements in some lipid parameters over weeks of dosing.
Exercise-physiology literature describes increased fatty acid oxidation with PPARδ agonism, which underlies claims about endurance.
Two-year rodent carcinogenicity studies conducted during development reported tumours across several organ systems, at doses relevant on an exposure basis.
Anti-doping analytical literature documents GW501516 in products marketed as supplements or research chemicals, sometimes undeclared.
What remains unknown
- Whether the rodent carcinogenicity signal translates to humans is unresolved and untested.
- No data exist on cumulative exposure from repeated recreational cycles.
- Long-term cardiovascular and hepatic outcomes are unstudied.
Safety and monitoring implications
- The reason this compound was abandoned is an unresolved cancer signal, not a lack of commercial interest — that is the central safety consideration.
- Endurance effects reported by users cannot offset an unquantified long-term risk.
- Products sold under this name are frequently mislabelled, so exposure is unverifiable without independent analysis.
Cited literature
- 1.Olson EJ, Pearce GL, Jones NP, Sprecher DL. (2012). Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology. Find on PubMed
- 2.Sprecher DL, Massien C, Pearce G, et al. (2007). Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arteriosclerosis, Thrombosis, and Vascular Biology. Find on PubMed
- 3.Geldof L, Deventer K, Van Eenoo P. (2014). Detection of selective androgen receptor modulators and GW501516 in doping control analysis. Drug Testing and Analysis. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Endurance and physique forums
PositiveFrequently described as improving work capacity and sustained pacing, with few immediate side effects reported.
Harm-reduction discussion groups
MixedA recurring split between users who dismiss the animal cancer findings and those who avoid the compound entirely on that basis.
Buying Cardarine / GW501516 in Australia: what to check first
APEDRA does not sell Cardarine / GW501516 or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.